Alavi Marcel V
Department of Ophthalmology, University of California, San Francisco, 10 Koret Way, 94143, San Francisco, CA, USA.
Adv Exp Med Biol. 2016;854:393-9. doi: 10.1007/978-3-319-17121-0_52.
Aging involves defined genetic, biochemical and cellular pathways that regulate lifespan. These pathways are called longevity pathways and they have relevance for many age-related diseases. In the eye, longevity pathways are involved in the major blinding diseases, cataract, glaucoma, age-related macular degeneration (AMD) and diabetic retinopathy. Pharmaceutical targeting of longevity pathways can extend healthy lifespan in laboratory model systems. This offers the possibility of therapeutic interventions to also delay onset or slow the progression of age-related eye diseases. I suggest that retinal degeneration may be viewed as accelerated aging of photoreceptors and that interventions extending healthy lifespan may also slow the pace of photoreceptor loss.
衰老涉及调控寿命的特定遗传、生化和细胞途径。这些途径被称为长寿途径，它们与许多与年龄相关的疾病相关。在眼睛中，长寿途径参与了主要的致盲疾病，如白内障、青光眼、年龄相关性黄斑变性（AMD）和糖尿病视网膜病变。在实验室模型系统中，针对长寿途径的药物靶向可以延长健康寿命。这为治疗干预提供了可能性，以延迟与年龄相关的眼部疾病的发病或减缓其进展。我认为视网膜变性可被视为光感受器的加速衰老，而延长健康寿命的干预措施也可能减缓光感受器丧失的速度。
